Cooper Financial Group Increases Holdings in Merck & Co., Inc. (NYSE:MRK)

Cooper Financial Group grew its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 50.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 4,550 shares of the company’s stock after acquiring an additional 1,525 shares during the quarter. Cooper Financial Group’s holdings in Merck & Co., Inc. were worth $415,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in MRK. Joseph P. Lucia & Associates LLC purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at about $25,000. Landmark Wealth Management LLC purchased a new stake in Merck & Co., Inc. in the 1st quarter worth about $25,000. Front Row Advisors LLC raised its position in Merck & Co., Inc. by 89.4% in the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock worth $26,000 after purchasing an additional 160 shares during the period. Okabena Investment Services Inc. purchased a new stake in Merck & Co., Inc. in the 4th quarter worth about $27,000. Finally, Western Pacific Wealth Management LP purchased a new stake in Merck & Co., Inc. in the 4th quarter worth about $29,000. 73.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on MRK. Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $89.00 to $102.00 in a research report on Wednesday, July 6th. Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research report on Friday, July 29th. Cowen upped their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a research note on Monday, June 27th. Atlantic Securities increased their price objective on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Finally, Erste Group Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.28.

Merck & Co., Inc. Trading Up 1.1 %

NYSE:MRK opened at $87.72 on Monday. Merck & Co., Inc. has a 52 week low of $70.89 and a 52 week high of $95.72. The firm has a 50 day moving average of $89.45 and a 200 day moving average of $87.64. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $222.22 billion, a price-to-earnings ratio of 13.43, a PEG ratio of 1.18 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.20. The company had revenue of $14.59 billion during the quarter, compared to analysts’ expectations of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. Merck & Co., Inc.’s revenue for the quarter was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.31 earnings per share. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be issued a $0.69 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.15%. Merck & Co., Inc.’s dividend payout ratio is currently 42.27%.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.